For patients with numbers of PD-L1+ CD49f+ CD133+ CTCs ≥ 2/ml (purple line, Fig. 5F), 3-years RFS rate was 7.4% and after 50 months all patients exhibited recurrent cervical cancer. This evidence concerns the gene PROM1 and cervical cancer.